Clinical and translational research

Clinical research at York is a joint venture, utilising the expertise and resources of the University, Hull York Medical School and York Teaching Hospital NHS Trust.

We aim to provide an environment that can deliver early phase trials (phase I and phase II) and support basic scientific research, which will result in high impact results.

Our Immunology, Haematology and Infection theme evolved from the Centre for Immunology and Infection, which was established in 2004.

The Centre established a close working relationship with York Teaching Hospital NHS Foundation Trust in 2009 to support basic and translational research. Jointly, we have successfully delivered several phase I and II trials over these years.

The research has mainly covered sexual health and infectious disease, but we have also delivered clinical trials in oncology, ophthalmology and rheumatology. In most cases we have successfully recruited to time and target.

Following the University’s acquisition of a Human Tissue Authority research license, the York Tissue Bank was established. This initiative aims to develop networks with the clinical care teams and provide researchers from both the hospital and university with access to human tissue for basic and translational research.

Ongoing projects

  • A phase IIa/IIb clinical trial to evaluate the therapeutic efficacy of ChAd63-KH vaccine in patients with persistent post kala-azar dermal leishmaniasis (PKDL).
  • TRINGA: A WHO-funded physiologic study using an investigational medical device: a temperature logging vaginal ring.
  • A phase II double-blind, placebo-controlled randomised trial to evaluate ChAd63-KH for prevention of PKDL in previously treated visceral leishmaniasis patients in Sudan.
  • A multicentre study in East Africa to determine the immune set point after treatment for visceral leishmaniasis using sodium stibogluconate / paromomycin combination therapy.

Completed projects

  • LEISH1: a phase II First-in-Human study to assess the safety and immunogenicity of a new Leishmania vaccine candidate ChAd63-KH.
  • NCRN464: A commercial randomised, double-blind, placebo-controlled, phase I/II trial of RNActive®-derived Cancer Vaccine (CV9104) in asymptomatic or minimally symptomatic patients with metastatic castrate-refractory prostate cancer.
  • ADON: A commercial 48-week, double-blind, randomised, multi-centre, parallel-group study comparing structural changes in the retina and evolution of visual function after immediate versus delayed treatment with fingolimod in patients with acute de-myelinating optic neuritis.
  • DAPIDAR: A randomised, double blind phase I study to assess the safety, pharmacokinetics and pharmacodynamics of single and 14 days dosing with two vaginal microbicide formulations containing either Darunavir, or Dapivirine plus Darunavir.
  • RADIUS: Rheumatology clinical trial, sponsored by Merck.
  • CV-9104-004: Oncology clinical trial.
  • MABGEL1: Sexual health/infectious disease clinical trial, sponsored by York Teaching Hospital NHS Foundation Trust.
  • MUCOVAC2: Sexual health/infectious disease clinical trial, sponsored by York Teaching Hospital NHS Foundation Trust.
  • GENTICEL: Sexual health/infectious diseases clinical trial, sponsored by Genticel.
  • GSK Hand Osteoarthritis: Rheumatology clinical trial, sponsored by GSK.
  • IgA Renal: Renal clinical trial, sponsored by Merck.
  • NASH: Hepatology clinical trial.